R D Chapurlat

Summary

Country: France

Publications

  1. ncbi [Treatment of postmenopausal osteoporosis]
    Roland Chapurlat
    Service de Rhumatologie et de Pathologie Osseuse, Hopital Edouard Herriot, 69437 Lyon Cedex 03
    Rev Prat 54:2120-6. 2004
  2. doi [Epidemiology of osteoporosis]
    Roland Chapurlat
    Universite de Lyon, Hopital E Herriot, France
    J Soc Biol 202:251-5. 2008
  3. ncbi A comparative review of the different techniques to assess hand bone damage in rheumatoid arthritis
    Anne Fouque-Aubert
    Unité Inserm U831, Service de Rhumatologie, Universite de Lyon 1, Hopital Edouard Herriot, 5, Place d Arsonval, 69437 Lyon, France
    Joint Bone Spine 77:212-7. 2010
  4. ncbi Medical therapy in adults with fibrous dysplasia of bone
    Roland D Chapurlat
    Department of Rheumatology, INSERM Research Unit 403, University Claude Bernard, Hopital E Herriot, Lyon, France
    J Bone Miner Res 21:P114-9. 2006
  5. ncbi Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study
    Roland D Chapurlat
    INSERM Research Unit 831 and Université de Lyon, Lyon, France
    J Bone Miner Res 22:1502-9. 2007
  6. ncbi Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture
    R D Chapurlat
    Department of Rheumatology and Bone Disease and INSERM Unit 403, Hopital E Herriot, 5 Place d Arsonval, 69437, Lyon, Cedex 03, France
    Osteoporos Int 17:1189-95. 2006
  7. doi Fibrous dysplasia of bone and McCune-Albright syndrome
    Roland D Chapurlat
    INSERM Research Unit 831, Universite de Lyon, and National Reference Centre for Fibrous Dysplasia of Bone, Department of Orthopaedics, Rheumatology and Bone Diseases, Hopital E Herriot, Lyon, France
    Best Pract Res Clin Rheumatol 22:55-69. 2008
  8. ncbi [New treatments in osteoporosis]
    R Chapurlat
    Service de rhumatologie et de pathologie osseuse et Inserm U403, Pavillon F, Hopital Edouard Herriot, 5, place Arsonval, 69437 Lyon 03, France
    Rev Med Interne 25:S573-9. 2004
  9. ncbi Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis
    Roland D Chapurlat
    Department of Rheumatology and Bone Diseases and INSERM U 403, Hopital E Herriot, Lyon, France
    Treat Endocrinol 4:115-25. 2005
  10. ncbi Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial
    R D Chapurlat
    Department of Rheumatology and Bone Diseases and INSERM U403, E Herriot Hospital, 69437 Lyon, France
    Osteoporos Int 16:842-8. 2005

Detail Information

Publications34

  1. ncbi [Treatment of postmenopausal osteoporosis]
    Roland Chapurlat
    Service de Rhumatologie et de Pathologie Osseuse, Hopital Edouard Herriot, 69437 Lyon Cedex 03
    Rev Prat 54:2120-6. 2004
    ..Teriparatide is a new bone forming agent to treat severe osteoporosis. Strontium ranelate is a new drug also reducing the risk of fractures that should be available soon...
  2. doi [Epidemiology of osteoporosis]
    Roland Chapurlat
    Universite de Lyon, Hopital E Herriot, France
    J Soc Biol 202:251-5. 2008
    ..Hip and vertebral fractures are associated with increased mortality and morbidity. Costs related to fragility fractures represent a significant burden for health care systems...
  3. ncbi A comparative review of the different techniques to assess hand bone damage in rheumatoid arthritis
    Anne Fouque-Aubert
    Unité Inserm U831, Service de Rhumatologie, Universite de Lyon 1, Hopital Edouard Herriot, 5, Place d Arsonval, 69437 Lyon, France
    Joint Bone Spine 77:212-7. 2010
    ....
  4. ncbi Medical therapy in adults with fibrous dysplasia of bone
    Roland D Chapurlat
    Department of Rheumatology, INSERM Research Unit 403, University Claude Bernard, Hopital E Herriot, Lyon, France
    J Bone Miner Res 21:P114-9. 2006
    ..Calcium, vitamin D, and phosphorus supplements may be useful in patients with deficiency. We are awaiting results from controlled trials testing bisphosphonates...
  5. ncbi Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study
    Roland D Chapurlat
    INSERM Research Unit 831 and Université de Lyon, Lyon, France
    J Bone Miner Res 22:1502-9. 2007
    ..We sought whether microdamage could rise in postmenopausal osteoporotic women on long-term bisphosphonates, as suggested by recent animal studies. We found few microcracks in iliac bone biopsies, despite a marked reduction in bone turnover...
  6. ncbi Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture
    R D Chapurlat
    Department of Rheumatology and Bone Disease and INSERM Unit 403, Hopital E Herriot, 5 Place d Arsonval, 69437, Lyon, Cedex 03, France
    Osteoporos Int 17:1189-95. 2006
    ....
  7. doi Fibrous dysplasia of bone and McCune-Albright syndrome
    Roland D Chapurlat
    INSERM Research Unit 831, Universite de Lyon, and National Reference Centre for Fibrous Dysplasia of Bone, Department of Orthopaedics, Rheumatology and Bone Diseases, Hopital E Herriot, Lyon, France
    Best Pract Res Clin Rheumatol 22:55-69. 2008
    ..Calcium, vitamin D and phosphorus supplements may be useful in some patients. Surgery is also helpful to prevent and treat fracture and deformities...
  8. ncbi [New treatments in osteoporosis]
    R Chapurlat
    Service de rhumatologie et de pathologie osseuse et Inserm U403, Pavillon F, Hopital Edouard Herriot, 5, place Arsonval, 69437 Lyon 03, France
    Rev Med Interne 25:S573-9. 2004
    ..In the next five years, new SERMs and inhibitors of RANK-ligand might be new treatment options...
  9. ncbi Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis
    Roland D Chapurlat
    Department of Rheumatology and Bone Diseases and INSERM U 403, Hopital E Herriot, Lyon, France
    Treat Endocrinol 4:115-25. 2005
    ..Zoledronic acid may also be an attractive option for the treatment of postmenopausal osteoporosis if a large ongoing trial proves that a single annual injection of this compound allows osteoporotic fracture risk reduction...
  10. ncbi Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial
    R D Chapurlat
    Department of Rheumatology and Bone Diseases and INSERM U403, E Herriot Hospital, 69437 Lyon, France
    Osteoporos Int 16:842-8. 2005
    ..So, the reduction in bone turnover induced by alendronate might be more important than BMD changes. The few women who lose the most BMD (more than 4% per year) might not benefit from the treatment...
  11. ncbi Single annual injectable treatment for postmenopausal osteoporosis
    Roland D Chapurlat
    Rheumatology Université de Lyon, INSERM U831, Department of Orthopedics and Rheumatology, Hopital E Herriot, Hospices Civils de Lyon, 69437 Lyon Cedex 03, France
    Expert Opin Drug Deliv 5:583-91. 2008
    ..Several treatments for postmenopausal osteoporosis have become available over the last decade, but adherence to treatment is inadequate and the prevention of non-vertebral fracture by those medications is still modest...
  12. ncbi Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes
    N R Portero-Muzy
    INSERM UMR 1033 et Université de Lyon, Lyon, France
    Bone 51:714-9. 2012
    ..The distinction of bone sites to study the early effects of anti-osteoporotic therapies appears meaningful in order to approach their site-specific anti-fracture efficacy...
  13. ncbi Assessment of vertebral fracture using densitometric morphometry
    F Duboeuf
    INSERM U403, Hopital Edouard Herriot, Lyon Cedex, France, and Prevention Sciences Group, University of California at San Francisco, USA
    J Clin Densitom 8:362-8. 2005
    ..The clinical utility of vertebral morphometry using densitometry may help screening patients with vertebral fracture, but technological improvements are necessary to improve image quality...
  14. doi Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study
    P Garnero
    INSERM Research Unit 1033, Lyon, France
    Osteoporos Int 24:489-94. 2013
    ....
  15. ncbi Risedronate: clinical usage
    R D Chapurlat
    Department of Rheumatology and Bone Diseases, Pavillon F, , 5 place d'Arsonval, 69437 Lyon, France
    Int J Clin Pract 55:275-8. 2001
    ..Risedronate is safe and well tolerated. Thus, risedronate is a new option for the management of postmenopausal osteoporosis, Paget's disease of bone and corticosteroid-induced bone loss...
  16. ncbi Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment
    R D Chapurlat
    Department of Rheumatology and Bone Diseases and INSERM U403, Pavillon F, Edouard Herriot Hospital, 5 Place d Arsonval, 69437 Lyon Cedex 03, France
    Bone 35:235-42. 2004
    ..Despite the lack of a control group, our results suggest that intravenous pamidronate improves radiological aspect in half of the patients with FD, decreases bone turnover, and may decrease pain intensity...
  17. doi Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)
    C Roux
    Department of Rheumatology, Cochin Hospital, Paris Descartes University, 27 rue du Faubourg St Jacques, 75659, Paris Cedex 14, France
    Osteoporos Int 23:2863-71. 2012
    ..Spine fractures had the greatest detrimental effect on EQ-5D, followed by major NHNV and hip fractures. Decreases in physical function and health status were greatest for spine or hip fractures...
  18. doi Rapid loss of appendicular skeletal muscle mass is associated with higher all-cause mortality in older men: the prospective MINOS study
    Pawel Szulc
    Inserm Unit 831, University of Lyon, Lyon, France
    Am J Clin Nutr 91:1227-36. 2010
    ..Changes in body composition underlying the association between weight loss and higher mortality are not clear...
  19. doi Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men
    Nicolas Vilayphiou
    INSERM Research Unit 831 and Université de Lyon, Lyon, France
    J Bone Miner Res 26:965-73. 2011
    ....
  20. ncbi Men with metabolic syndrome have lower bone mineral density but lower fracture risk--the MINOS study
    Pawel Szulc
    INSERM 831 Unit, Hopital Edouard Herriot, University of Lyon, Lyon, France
    J Bone Miner Res 25:1446-54. 2010
    ..MetS probably is not a meaningful concept in the context of bone metabolism. Analysis of its association with bone-related variables may obscure the pathophysiologic links of its components with bone status...
  21. doi Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women
    Nicolas Vilayphiou
    INSERM Research Unit 831 and Université de Lyon, Lyon, France
    Bone 46:1030-7. 2010
    ..We have also shown that muFEA parameters obtained with distal tibia data were associated with prevalent fractures with a similar magnitude that with parameters obtained at the radius...
  22. ncbi [Evaluation of vertebral fractures with dual energy absorptiometry: is it an alternative to conventional radiography?]
    Francois Duboeuf
    Unité Inserm 403 Hôpital Edouard Herriot Pav F, Service de rhumatologie 5, place d Arsonval F 69437 Lyon
    Rev Med Suisse Romande 124:67-9. 2004
    ..Nevertheless, its good negative predictive value may allow its use as a screening tool in a high risk population. Main progress should be performed on the image definition in order to increase the diagnostic sensitivity of the technique...
  23. doi Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial
    R D Chapurlat
    Inserm U1033, Universite de Lyon, Hopital E Herriot, Lyon, France
    Osteoporos Int 24:311-20. 2013
    ....
  24. doi FRAX® probabilities and risk of major osteoporotic fracture in France
    C M Couris
    Pôle IMER, Hospices Civils de Lyon, Lyon, France
    Osteoporos Int 23:2321-7. 2012
    ....
  25. doi Bone microdamage: a clinical perspective
    R D Chapurlat
    INSERM Research Unit 831, Universite de Lyon, Hopital E Herriot, Hospices Civils de Lyon, 69437 Lyon Cedex 03, France
    Osteoporos Int 20:1299-308. 2009
    ..Microdamage accumulation due to fatigue loading may lead to fracture. In addition, several studies using animal models have suggested in recent years that bisphosphonates might increase microdamage accumulation...
  26. ncbi Contribution of trabecular and cortical components to biomechanical behavior of human vertebrae: an ex vivo study
    Jean Paul Roux
    INSERM Research Unit 831, Universite de Lyon, Lyon, France
    J Bone Miner Res 25:356-61. 2010
    ....
  27. doi Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
    C B Confavreux
    Department of Rheumatology, INSERM U831 Université de Lyon, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon 69003, France
    Osteoporos Int 22:1023-36. 2011
    ..In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases...
  28. doi Staining procedure for the detection of microcracks: application to ewe bone
    N R Portero-Muzy
    Faculté de médecine Lyon Est, Domaine Laënnec La Buire, INSERM UMR 1033 and Université de Lyon, Lyon, France
    Bone 49:917-9. 2011
    ..We conclude that the staining procedures should differ when examining ewe or human bone. This may be due to differences in bone matrix composition...
  29. ncbi Influence of RANKL inhibition on immune system in the treatment of bone diseases
    Anne Fouque-Aubert
    Service de Rhumatologie, Hopital Edouard Herriot, 5 Place d Arsonval, 69437 Lyon Cedex, France
    Joint Bone Spine 75:5-10. 2008
    ..So, blocking RANKL could interplay with immune cells and have systemic effects. Here, we review biological data regarding potential consequences of RANKL blocking on the immune system...
  30. ncbi Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?
    Roland D Chapurlat
    Prevention Sciences Group, Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
    Osteoporos Int 13:738-44. 2002
    ..So, the use of follow-up measures of bone turnover may be based on patient and physician preferences...
  31. ncbi Drug insight: Bisphosphonates for postmenopausal osteoporosis
    Roland D Chapurlat
    University Claude Bernard, Lyon, France
    Nat Clin Pract Endocrinol Metab 2:211-9; quiz following 238. 2006
    ..Intravenous administration of bisphosphonates in women with osteoporosis, which is currently under investigation, might be an interesting future option for women who cannot tolerate oral regimens, and for enhancing compliance...
  32. ncbi Review of ibandronate in the treatment of osteoporosis
    Roland D Chapurlat
    Department of Rheumatology and Bone Diseases, Hôpital E Herriot and Claude Bernard University of Lyon, 5 Place d Arsonval, France
    Expert Opin Pharmacother 4:391-6. 2003
    ..v. every 3 months. Thus, ibandronate can be considered as a promising new option for the treatment of postmenopausal osteoporotic women...
  33. ncbi Misleading clavicular osteolytic lesion revealing fibrous dysplasia
    Houda Maaroufi
    Joint Bone Spine 73:475-7. 2006
  34. pmc Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study
    Henrik Toft Sørensen
    Department of Clinical Epidemiology, Aarhus University Hospital, 8000 Aarhus C, Denmark
    BMJ 336:813-6. 2008
    ..To assess the association between atrial fibrillation and flutter and use of bisphosphonates for osteoporosis among women...